OncoCyte (OCX) News Today $3.18 +0.45 (+16.30%) Closing price 06/17/2025Extended Trading$3.18 0.00 (0.00%) As of 06/17/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleJune 17, 2025 | globenewswire.comAWM Investment Company Inc. Has $1.85 Million Position in OncoCyte Co. (NASDAQ:OCX)May 23, 2025 | marketbeat.comOncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement PotentialMay 21, 2025 | nasdaq.comOncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 20, 2025 | finanznachrichten.deMedicare Boosts Reimbursement for Oncocyte’s Flagship TechnologyMay 19, 2025 | finance.yahoo.comMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 19, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Receives "Buy" Rating from Needham & Company LLCMay 15, 2025 | marketbeat.comOncoCyte (NASDAQ:OCX) Releases Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13, 2025 | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13, 2025 | msn.comOncoCyte Corporation (OCX) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comOncocyte Reports Q1 2025 Results and Business ProgressMay 12, 2025 | globenewswire.comOncoCyte Q1 2025 Earnings PreviewMay 11, 2025 | msn.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Broadwood Capital Inc.May 8, 2025 | marketbeat.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Trading Down 3.1% - Here's What HappenedMay 2, 2025 | marketbeat.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)April 8, 2025 | marketbeat.comOncoCyte Co. (NASDAQ:OCX) Sees Large Growth in Short InterestApril 4, 2025 | marketbeat.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comApril 1, 2025 | marketbeat.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Pura Vida Investments LLCMarch 31, 2025 | marketbeat.comOncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at Lake Street CapitalMarch 29, 2025 | marketbeat.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncoCyte's (OCX) Equal Weight Rating Reiterated at StephensMarch 26, 2025 | marketbeat.comOncoCyte's (OCX) "Buy" Rating Reaffirmed at Needham & Company LLCMarch 26, 2025 | marketbeat.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comOncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comOncoCyte (NASDAQ:OCX) Announces Earnings ResultsMarch 25, 2025 | marketbeat.comOncocyte targets $20M in recurring revenue from 20 transplant centers by 2025March 24, 2025 | msn.comOncoCyte Corporation (OCX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comOncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsMarch 24, 2025 | globenewswire.comOncoCyte Corporation (OCX): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comOncoCyte (NASDAQ:OCX) Trading Up 14.7% - Should You Buy?March 5, 2025 | marketbeat.comOncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025March 4, 2025 | msn.comOncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.comOncocyte corp CFO buys $200,000 in stockFebruary 12, 2025 | msn.comAndrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) StockFebruary 12, 2025 | insidertrades.comOncocyte corp's Patrick Smith acquires shares worth $2.2 millionFebruary 11, 2025 | msn.comBroadwood Partners acquires OncoCyte shares worth $9.24 millionFebruary 11, 2025 | msn.comOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 11, 2025 | globenewswire.comOncocyte Prices $29.1 Million Equity OfferingFebruary 10, 2025 | globenewswire.comOncocyte corp investor Patrick Smith buys $1,839 in sharesFebruary 5, 2025 | msn.com Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.001.01▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼02▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Humacyte News Amarin News Prothena News Benitec Biopharma News Heron Therapeutics News SNDL News Vor Biopharma News Aura Biosciences News Astria Therapeutics News Aerovate Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
